Biotech Values

[DewDiligence]

NUVO – Another buyout?

http://biz.yahoo.com/prnews/080924/aqw115.html

›Nuvelo to Host Conference Call on Thursday, September 25, 2008

Wednesday September 24, 9:01 pm ET

SAN CARLOS, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO ) today announced that it will hold a conference call and webcast at 8:30 a.m. Eastern time (5:30 a.m. Pacific Time) on Thursday, September 25, 2008 to discuss company news.

To participate in the conference call, please dial 866-854-8095 for domestic callers and 706-634-8567 for international callers and reference conference passcode 66253667. A telephone replay of the conference call will be available through Wednesday, October 1, 2008. To access the replay, please dial 800-642-1687 for domestic callers and 706-645-9291 for international callers and reference conference passcode 66253667.

This call is being webcast by Thomson/CCBN. The webcast can be accessed via Nuvelo's website at http://www.nuvelo.com and is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor which has completed Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and NU206, a Wnt pathway modulator in Phase 1 development for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.‹